Takeda Pharmaceutical Company Limited(4502) News

Takeda Announces U.S. FDA Accepts NDA and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

U.S. FDA Accepts NDA and Grants Priority Review for Takeda's Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepy Type 1

Earnings Report (Kessan Tanshin) for the Nine-month Period Ended December 31, 2025 (IFRS, Consolidated)

Takeda Pharma, Net Income Forecast for the Fiscal Year Revised Upward by 1%

Takeda’s Zasocitinib Landmark Ph3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in PV

The 149th (interim period) Business Report

Semi-annual Securities Report (The semi-annual of 149th Business Term) for The Six-month Period Ended September 30, 2025

Earnings Report (Kessan Tanshin) for the Six-month Period Ended September 30, 2025 (IFRS, Consolidated)

Takeda Pharma, Net Income Forecast for the Fiscal Year Revised Downward by 33%

Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)

Takeda Provides Update on Cell Therapy Research

Information About General Reserve and Other Voluntary Reserves

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

Statement on Inadvertent Abstract Disclosure for Opevorexton (TAK-861) by World Sleep Congress

Earnings Report (Kessan Tanshin) for the Three-month Period Ended June 30, 2025 (IFRS, Consolidated)

Takeda Pharma, Apr-Jun (1Q) Net Income Increases by 30%

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

Corporate Governance Report 2025/07/09

Takeda Completes Disposal of Treasury Shares under the LTIP for Company Group Employees Outside of Japan with Partial Forfeiture